{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:10:21Z","timestamp":1741129821914,"version":"3.38.0"},"reference-count":43,"publisher":"ECO-Vector LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/deed.ru"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["annaly-nevrologii.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:p>The review provides modern understanding of the pathogenesis of progressive multifocal leukoencephalopathy (PML), a severe and potentially fatal form of multiple-lesion disorder of the brain white matter. Information about the frequency of its development in patients with disease-modifying treatment of multiple sclerosis is analyzed. The algorithms of optimization of PML risks in this category of patients with multiple sclerosis are described in detail. Summarized are the data on most significant PML biomarkers, the search for which is currently under way in many centers across the world. The first case of PML in Russia is briefly described.<\/jats:p>","DOI":"10.25692\/acen.2018.4.9","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T03:22:35Z","timestamp":1737602555000},"update-policy":"https:\/\/doi.org\/10.54101\/crossmarkpolicy2021","source":"Crossref","is-referenced-by-count":0,"title":["Progressive multifocal leukoencephalopathy as a complication of disease-modifying treatment of multiple sclerosis"],"prefix":"10.17816","volume":"12","author":[{"given":"M.N.","family":"Zakharova","sequence":"first","affiliation":[{"name":"Research \u0421enter of Neurology, Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.V.","family":"Lysogorskaia","sequence":"first","affiliation":[{"name":"Research \u0421enter of Neurology, Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.V.","family":"Ivanova","sequence":"first","affiliation":[{"name":"Research \u0421enter of Neurology, Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.A.","family":"Kochergin","sequence":"first","affiliation":[{"name":"Research \u0421enter of Neurology, Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.E.","family":"Korzhova","sequence":"first","affiliation":[{"name":"Research \u0421enter of Neurology, Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7284","reference":[{"key":"ref1","unstructured":"Zavalishin I.A., Zakharova M.N. [Multiple sclerosis: results and perspectives of the study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 1982; 82(2): 161\u2013167. (In Russ.)"},{"key":"ref2","unstructured":"Zavalishin I.A., Zakharova M.N., Zhuchenko T.D., Peresedova A.V. [Etiology and pathogenesis of multiple sclerosis]. In: Zavalishin I.A., Golovkin V.I. (eds.) Rasseyannyi skleros. Izbrannye voprosy teorii i praktiki [Multiple Sclerosis. Selected issues of theory and practice]. Moscow: Ministry of Health of Russia, Research center of neurology, RAMS, 2000: 537\u2013579. (In Russ.)"},{"key":"ref3","unstructured":"Bisaga G.N., Kovalenko A.V., Isayeva G.E. et al. [The use of mesenchymal stem cells in optic atrophy in patients with multiple sclerosis: a pilot study]. Annals of clinical and experimental neurology 2017; 11(2): 26\u201331. (In Russ.)"},{"key":"ref4","unstructured":"Ryabtseva M.S., Negudova N.P., Batuashvili T.A., Simutenko L.V. [Experimental evaluation of bioequivalence of original and reproduced peptide preparations in multiple sclerosis]. Annals of clinical and experimental neurology 2018; 12(2): 39\u201344. (In Russ.)"},{"key":"ref5","unstructured":"Votintseva M.V., Petrov A.M., Stolyarov I.D. [Drugs based on monoclonal antibodies: the present and the future in the treatment of multiple sclerosis (based on the materials of the 32nd Congress of the European Committee for the Treatment and Research of Multiple Sclerosis \u2013 ECTRIMS)]. Annals of clinical and experimental neurology 2017; 11(2): 83\u201388. (In Russ.)"},{"key":"ref6","unstructured":"Zakharova M.N., Logunov D.Yu., Kochergin I.A., Bakulin I.S. [Endogenous retroviruses: from basic research to etiotropic therapy for multiple sclerosis]. Annals of clinical and experimental neurology 2015; 9(4): 49\u201353. (In Russ.)"},{"key":"ref7","unstructured":"Zakharova M.N. Lipid myelin. In: Multiple sclerosis. Selected questions of theory and practice. In: Zavalishin I.A., Golovkin V.I. (eds.) Rasseyannyi skleros. Izbrannye voprosy teorii i praktiki [Multiple Sclerosis. Selected issues of theory and practice]. Moscow: Ministry of Health of Russia, Research center of neurology, RAMS, 2000: 69\u201396. (In Russ.)"},{"key":"ref8","unstructured":"Boyko A.N., Lash N.Yu., Sharanova S.N. et al. A comparative placebo-controlled clinical trial of the efficacy and safety of glatiramer acetate 20 mg in patients with relapsing multiple sclerosis: the results of the first year of follow-up. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016. 10(2): 61\u201362. (In Russ.)"},{"key":"ref9","unstructured":"Korzhova Yu.E., Vorobyova A.A., Ivanova M.V. et al. A comparison of the efficacy of natalizumab or fingolimod as second-line drugs in patients with multiple sclerosis. Medica mente. Lechim s umom 2016; (1): 63\u201366. (In Russ.)"},{"key":"ref10","unstructured":"Hallervorden J. Eigennartige and nicht rubriziebare prozesse. In: Bumke O. (ed.) Handbuch der Geiteskranheiten, Die Anatomie der Phychosen. Berlin: Springer; 1930; 2: 1063\u20131107."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Astrom K.E., Mancell E.L., Richardson E.P.J. Progressive multifocal encephalopathy: A hitharto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain 1958; 81: 99\u2013111. PMID: 13523006.","DOI":"10.1093\/brain\/81.1.93"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"ZuRhein G.M., Chou S.M. Particles resembling papova-virus in human cerebral demyelinating disease. Science 1965; 148: 1477\u20131479. PMID: 14301897.","DOI":"10.1126\/science.148.3676.1477"},{"key":"ref13","unstructured":"ZuRhein G.M. Association of papova-virions with a human demyelination disease (progressive multifocal leukoencephalopathy). Prog Med Virol 1969; 11: 185\u2013248. PMID: 4906870."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Padgett B.L., Walker D.L., ZuRhein G.M. et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1: 1257\u20131260. PMID: 4104715.","DOI":"10.1016\/S0140-6736(71)91777-6"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Frisque R.J., Bream G.L., Cannella M.T. Human polyomavirus JC virus genome. J Virol 1984; 51: 458\u2013469. PMID: 6086957.","DOI":"10.1128\/jvi.51.2.458-469.1984"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Gardner S.D., Feild A.M., Colleman D.V., Hulme B. New human papovavirus (BK) isolated from urine after renal transplantation. Lancet 1971. 1: 1253\u20131257. PMID: 4104714.","DOI":"10.1016\/S0140-6736(71)91776-4"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-32957-9_2"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir256"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.1858"},{"key":"ref20","unstructured":"Zakharova M.N. [Progressive multifocal leukoencephalopathy (literature review)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2012; 112(9-2): 29\u201333. (In Russ.)"},{"key":"ref21","unstructured":"Physician Information and Management Guidelines for Multiple Sclerosis patients on TYSABRI Therapy. European Medicines Agency. 2016. https:\/\/www.medicines.org.uk\/emc\/rmm\/1199\/Document"},{"key":"ref22","unstructured":"Carrillo-Infante C., Richman S., Yu B. et al. Functional and survival outcomes of asymptomatic progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: 2015 update. ECTRIMS Online Library 2016: EP1528."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Power C., Gladden J.G., Halliday W. et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000; 54: 743\u2013746. PMID: 10680816.","DOI":"10.1212\/WNL.54.3.743"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/13550280152537184"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20492"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2017.03.002"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/art.24966"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.04.010"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00138"},{"key":"ref32","unstructured":"\u0413\u0443\u0441\u0435\u0432 \u0415.\u0418., \u0413\u0435\u0445\u0442 \u0410.\u0411. (\u0440\u0435\u0434). \u0412\u0441\u0435\u0440\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0435 \u043e\u0431\u0449\u0435\u0441\u0442\u0432\u043e \u043d\u0435\u0432\u0440\u043e\u043b\u043e\u0433\u043e\u0432. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438. \u0420\u0430\u0441\u0441\u0435\u044f\u043d\u043d\u044b\u0439 \u0441\u043a\u043b\u0435\u0440\u043e\u0437. \u041c.: \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432 \u0420\u043e\u0441\u0441\u0438\u0438, 2018. 129 c."},{"key":"ref33","unstructured":"Gusev E.I., Gekht A.B. (eds.). Vserossiyskoye obshchestvo nevrologov. Klinicheskiye rekomendatsii. Rasseyannyy skleroz [Russian Society of Neurologists. Clinical recommendations. Multiple sclerosis]. Moscow: Ministry of Health of Russia, 2018. 129 p. (In Russ.)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8931-7"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.05.006"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160277"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513513208"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(2002010)32:10<2905::AID-IMMU2905>3.0.CO;2-6"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.06.008"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a351fb"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002314"},{"key":"ref43","unstructured":"Zakharova M.N., Lysogorskaia E.V., Trushnikova T.N., Zhelnin A.V. [The case of development of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis on the background of taking natalizumab]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2018; 8(2): 106\u2013108. (In Russ.)"}],"container-title":["Annals of Clinical and Experimental Neurology"],"original-title":[],"language":"ru","link":[{"URL":"https:\/\/annaly-nevrologii.com\/journal\/pathID\/article\/viewFile\/552\/442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/annaly-nevrologii.com\/journal\/pathID\/article\/viewFile\/552\/442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T22:37:24Z","timestamp":1741127844000},"score":1,"resource":{"primary":{"URL":"http:\/\/annaly-nevrologii.com\/journal\/index.php\/pathID\/article\/view\/552"}},"subtitle":["\u041f\u0440\u043e\u0433\u0440\u0435\u0441\u0441\u0438\u0440\u0443\u044e\u0449\u0430\u044f \u043c\u0443\u043b\u044c\u0442\u0438\u0444\u043e\u043a\u0430\u043b\u044c\u043d\u0430\u044f \u043b\u0435\u0439\u043a\u043e\u044d\u043d\u0446\u0435\u0444\u0430\u043b\u043e\u043f\u0430\u0442\u0438\u044f \u043a\u0430\u043a \u043e\u0441\u043b\u043e\u0436\u043d\u0435\u043d\u0438\u0435 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430\u043c\u0438, \u0438\u0437\u043c\u0435\u043d\u044f\u044e\u0449\u0438\u043c\u0438 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 \u0440\u0430\u0441\u0441\u0435\u044f\u043d\u043d\u043e\u0433\u043e \u0441\u043a\u043b\u0435\u0440\u043e\u0437\u0430"],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.25692\/acen.2018.4.9","relation":{},"ISSN":["2075-5473","2409-2533"],"issn-type":[{"type":"print","value":"2075-5473"},{"type":"electronic","value":"2409-2533"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}